Devices for overcoming biological barriers: The use of physical forces to disrupt the barriers

Advanced Drug Delivery Reviews

Volumn 65, Issue 1, 2013, Pages 100-103

  Mitragotri, Samir ^a  

^a University of California   (United States)

Author keywords

Devices; Drug delivery; Enhancer; Non invasive; Physical; Skin

Indexed keywords

BIOLOGICAL BARRIER; BLOOD-BRAIN BARRIER; DEVICES; ELECTRIC DEVICES; ENHANCER; MICRONEEDLES; NON-INVASIVE; NUCLEAR MEMBRANES; PHYSICAL; PHYSICAL FORCE; PHYSICAL METHODS; PROTECTIVE FUNCTION; WORKING PRINCIPLES;

CELL MEMBRANES; SKIN;

DRUG DELIVERY;

DEXAMETHASONE; LIDOCAINE;

ACOUSTIC ABLATION; DRUG DELIVERY SYSTEM; ELECTRIC CURRENT; ELECTRICAL EQUIPMENT; ELECTROPORATION; HEARING AID; HUMAN; IONTOPHORESIS; LASER; MASS IMMUNIZATION; MEDICAL DEVICE; MICRONEEDLE; MOLECULAR WEIGHT; NON INVASIVE PROCEDURE; NONHUMAN; OPTICAL INSTRUMENTATION; PERMEABILITY BARRIER; PRIORITY JOURNAL; RADIOFREQUENCY; REVIEW; SONOPHORESIS; SONOPORATION; ULTRASOUND;

ANIMALS; BLOOD-BRAIN BARRIER; CELL MEMBRANE; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; SKIN; TECHNOLOGY, PHARMACEUTICAL;

EID: 84873272478     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.07.016     Document Type: Review

References (80)

1. Scheuplein R.J., Blank I.H. Permeability of the skin. Physiol. Rev. 1971, 51(4):702-747.
2. Lichtenberger L.M. Membranes and barriers: with a focus on the gastric mucosal barrier. Clin. Invest. Med. 1987, 10(3):181-188.
3. Sykova E., Nicholson C. Diffusion in brain extracellular space. Physiol. Rev. 2008, 88(4):1277-1340.
4. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8(2):129-138.
5. Hsu T., Mitragotri S. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(38):15816-15821.
6. Karande P., Mitragotri S. High throughput screening of transdermal formulations. Pharm. Res. 2002, 19(5):655-660.
7. Touitou E., et al. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control. Release 2000, 65(3):403-418.
8. Bruno K. Using drug-excipient interactions for siRNA delivery. Adv. Drug Deliv. Rev. 2011, 63(13):1210-1226.
9. Mahon K.P., et al. Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconjug. Chem. 2010, 21(8):1448-1454.
10. Mathiowitz E., et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997, 386(6623):410-414.
11. Arora A., Prausnitz M.R., Mitragotri S. Micro-scale devices for transdermal drug delivery. Int. J. Pharm. 2008, 364(2):227-236.
12. Prausnitz M.R., Mitragotri S., Langer R. Current status and future potential of transdermal drug delivery. Nat. Rev. Drug Discov. 2004, 3(2):115-124.
13. Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat. Rev. Drug Discov. 2005, 4(3):255-260.
14. Prausnitz M.R. Reversible skin permeabilization for transdermal delivery of macromolecules. Crit. Rev. Ther. Drug Carrier Syst. 1997, 14(4):455-483.
15. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat. Rev. Drug Discov. 2006, 5(7):543-548.
16. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 2004, 56(5):581-587.
17. Mitragotri S., Blankschtein D., Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995, 269(5225):850-853.
18. Paliwal S., Menon G.K., Mitragotri S. Low-frequency sonophoresis: ultrastructural basis for stratum corneum permeability assessed using quantum dots. J. Invest. Dermatol. 2006, 126(5):1095-1101.
19. Kost J., et al. Transdermal monitoring of glucose and other analytes using ultrasound. Nat. Med. 2000, 6(3):347-350.
20. Mitragotri S., et al. Transdermal extraction of analytes using low-frequency ultrasound. Pharm. Res. 2000, 17(4):466-470.
21. Cantrell J.T., McArthur M.J., Pishko M.V. Transdermal extraction of interstitial fluid by low-frequency ultrasound quantified with 3H2O as a tracer molecule. J. Pharm. Sci. 2000, 89(9):1170-1179.
22. Lavon I., Kost J. Ultrasound and transdermal drug delivery. Drug Discov. Today 2004, 9(15):670-676.
23. Kim do K., Choi S.W., Kwak Y.H. The effect of SonoPrep(R) on EMLA(R) cream application for pain relief prior to intravenous cannulation. Eur. J. Pediatr. 2012, 171(6):985-988.
24. Vykhodtseva N.I., et al. Use of focused ultrasound for local destruction of different brain structures. Zh. Nevropatol. Psikhiatr. Im. S S Korsakova 1976, 76(12):1810-1816.
25. Hynynen K., et al. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001, 220(3):640-646.
26. Mesiwala A.H., et al. High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound Med. Biol. 2002, 28(3):389-400.
27. Taniyama Y., et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002, 105(10):1233-1239.
28. Vykhodtseva N., McDannold N., Hynynen K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 2008, 48(4):279-296.
29. Doomernik D.E., et al. Advancements in catheter-directed ultrasound-accelerated thrombolysis. J. Endovasc. Ther. 2011, 18(3):418-434.
30. Huber P.E., et al. A comparison of shock wave and sinusoidal-focused ultrasound-induced localized transfection of HeLa cells. Ultrasound Med. Biol. 1999, 25(9):1451-1457.
31. Tata D.B., Dunn F., Tindall D.J. Selective clinical ultrasound signals mediate differential gene transfer and expression in two human prostate cancer cell lines: LnCap and PC-3. Biochem. Biophys. Res. Commun. 1997, 234(1):64-67.
32. Miller D.L., et al. Ultrasonic enhancement of gene transfection in murine melanoma tumors. Ultrasound Med. Biol. 1999, 25(9):1425-1430.
33. Huber P.E., Pfisterer P. In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther. 2000, 7(17):1516-1525.
34. Manome Y., et al. Ultrasound facilitates transduction of naked plasmid DNA into colon carcinoma cells in vitro and in vivo. Hum. Gene Ther. 2000, 11(11):1521-1528.
35. Kalia Y.N., et al. Iontophoretic drug delivery. Adv. Drug Deliv. Rev. 2004, 56(5):619-658.
36. Spierings E.L., Brevard J.A., Katz N.P. Two-minute skin anesthesia through ultrasound pretreatment and iontophoretic delivery of a topical anesthetic: a feasibility study. Pain Med. 2008, 9(1):55-59.
37. Lark M.R., Gangarosa L.P. Iontophoresis: an effective modality for the treatment of inflammatory disorders of the temporomandibular joint and myofascial pain. Cranio 1990, 8(2):108-119.
38. Langkjaer L., et al. Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J. Control. Release 1998, 51(1):47-56.
39. Raiman J., et al. Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis. Eur. J. Pharm. Sci. 2004, 21(2-3):371-377.
40. Coury A.J., et al. Development of a screening system for cystic fibrosis. Clin. Chem. 1983, 29(9):1593-1597.
41. Guy R.H., et al. Iontophoresis: electrorepulsion and electroosmosis. J. Control. Release 2000, 64(1-3):129-132.
42. Sieg A., Guy R.H., Delgado-Charro M.B. Electroosmosis in transdermal iontophoresis: implications for noninvasive and calibration-free glucose monitoring. Biophys. J. 2004, 87(5):3344-3350.
43. Tamada J.A., et al. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA 1999, 282(19):1839-1844.
44. Prausnitz M.R., et al. Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(22):10504-10508.
45. Banga A.K., Prausnitz M.R. Assessing the potential of skin electroporation for the delivery of protein- and gene-based drugs. Trends Biotechnol. 1998, 16(10):408-412.
46. Heller L.C., Ugen K., Heller R. Electroporation for targeted gene transfer. Expert Opin. Drug Deliv. 2005, 2(2):255-268.
47. Mitragotri S. Innovation - current status and future prospects of needle-free liquid jet injectors. Nat. Rev. Drug Discov. 2006, 5(7):543-548.
48. Schramm J., Mitragotri S. Transdermal drug delivery by jet injectors: energetics of jet formation and penetration. Pharm. Res. 2002, 19(11):1673-1679.
49. Weniger B.G. Jet injection of vaccines: overview and challenges for mass vaccination with jet injections (JIs). Innovative Administration Systems for Vaccines 2003, Rockville, Maryland.
50. Baxter J., Mitragotri S. Needle-free liquid jet injections: mechanisms and applications. Expert Rev. Med. Devices 2006, 3(5):565-574.
51. Jackson L.A., et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 2001, 19(32):4703-4709.
52. Arora A., et al. Needle-free delivery of macromolecules across the skin by nanoliter-volume pulsed microjets. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(11):4255-4260.
53. Stachowiak J.C., et al. Dynamic control of needle-free jet injection. J. Control. Release 2009, 135(2):104-112.
54. Taberner A., Hogan N.C., Hunter I.W. Needle-free jet injection using real-time controlled linear Lorentz-force actuators. Med. Eng. Phys. 2012, Epub: PMID: 22245386.
55. Kendall M., Mitchell T., Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J. Biomech. 2004, 37(11):1733-1741.
56. Mulholland W.J., et al. Characterization of powdered epidermal vaccine delivery with multiphoton microscopy. Phys. Med. Biol. 2004, 49(22):5043-5058.
57. Drape R.J., et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006, 24(21):4475-4481.
58. Kanazawa T., et al. Local gene expression and immune responses of vaginal DNA vaccination using a needle-free injector. Int. J. Pharm. 2010, 396(1-2):11-16.
59. Dabarakis N.N., et al. Needle-less local anesthesia: clinical evaluation of the effectiveness of the jet anesthesia Injex in local anesthesia in dentistry. Quintessence Int. 2007, 38(10):E572-E576.
60. Prausnitz M.R., Ackley D., Gyory J. Microneedles for transdermal drug delivery. Modified Release Drug Delivery Systems 2003, 513-522. Marcel Dekker, New York. H.J. Rathbone, M. Roberts (Eds.).
61. Park J.H., Allen M.G., Prausnitz M.R. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2004, 4:2654-2657.
62. Martanto W., et al. Transdermal delivery of insulin using microneedles in vivo. Pharm. Res. 2004, 21(6):947-952.
63. McAllister D.V., et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(24):13755-13760.
64. Mikszta J.A., et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 2002, 8(4):415-419.
65. Wermeling D.P., et al. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(6):2058-2063.
66. Gupta J., et al. Rapid local anesthesia in humans using minimally invasive microneedles. Clin. J. Pain 2012, 28(2):129-135.
67. Gupta J., Felner E.I., Prausnitz M.R. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol. Ther. 2011, 13(4):451-456.
68. Matriano J.A., et al. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. 2002, 19(1):63-70.
69. Widera G., et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 2006, 24(10):1653-1664.
70. Cormier M., et al. Transdermal delivery of desmopressin using a coated microneedle array patch system. J. Control. Release 2004, 97(3):503-511.
71. Kim Y.C., Park J.H., Prausnitz M.R. Microneedles for drug and vaccine delivery. Adv. Drug Deliv. Rev. 2012, Epub: PMID: 22575858.
72. Vemulapalli V., et al. In vivo iontophoretic delivery of salmon calcitonin across microporated skin. J. Pharm. Sci. 2012, 101(8):2861-2869.
73. Singh T.R., et al. Microporation techniques for enhanced delivery of therapeutic agents. Recent Pat. Drug Deliv. Formul. 2010, 4(1):1-17.
74. Bramson J., et al. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther. 2003, 10(3):251-260.
75. Birchall J., et al. Cutaneous gene expression of plasmid DNA in excised human skin following delivery via microchannels created by radio frequency ablation. Int. J. Pharm. 2006, 312(1-2):15-23.
76. Kalluri H., Banga A.K. Transdermal delivery of proteins. AAPS PharmSciTech 2011, 12(1):431-441.
77. Pickup J.C. Insulin-pump therapy for type 1 diabetes mellitus. N. Engl. J. Med. 2012, 366(17):1616-1624.
78. Stevenson C.L., Santini J.T., Langer R. Reservoir-based drug delivery systems utilizing microtechnology. Adv. Drug Deliv. Rev. 2012.
79. Farra R., et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci. Transl. Med. 2012, 4(122):122ra21.
80. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6(1):67-74.